The effect of apatinib combined with chemotherapy or targeted therapy on non ‐small cell lung cancer in vitro and vivo

ConclusionsThe efficacy of apatinib combination is better than that of monotherapy, and there is no significant difference in toxicity of important organs, which suggests the feasibility of a combination of apatinib in the treatment of non ‐small cell lung cancer.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Conclusion: Anti-GABA-B receptor encephalitis mainly occurred in middle-aged and elderly men, and the disease onset was relatively sudden. Before disease onset, some patients experienced fever and non-specific respiratory symptoms, which mainly manifested as frequent epileptic seizures, cognitive dysfunction, and abnormal mental behavior. MRI and PET-CT revealed abnormal signals and local metabolism, respectively, in the temporal lobe. Moreover, the disease has a close relationship with lung cancer, which requires long-term follow-up observation.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
The predominant metastatic site of lung cancer (LC) is the brain. Although outdated, conventional cisplatin treatment is still the main therapeutic approach for patients with advanced non-small cell lung cance...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Research Source Type: research
ew D. Beggs Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting targets along this pathway, in enhancing radiotherapy response. We identified several studies using in vitro cancer cell lines, in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study investigates sampling adequacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for PD-L1 testing when compared to other methods. Furthermore, the relationship between clinico-pathological characteristics and PD-L1 expression in the study population have been examined. METHODS: Five hundred seventy-seven NSCLC specimens were analysed from consecutive patients with NSCLC across six centres in United Kingdom and one in the United States between January 2015 and December 2016. MAIN RESULTS: In the EBUS-TBNA group (189 specimens), the overall percentage of patients with succe...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical component of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung cancer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of syst...
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: ADULT BRAIN Source Type: research
Lung cancer patients frequently develop brain metastases (BM). For example, approximately 30% of radically treated stage III non-small cell lung cancer (NSCLC) patients present with symptomatic BM in the course of their disease, despite being treated with radical chemoradiotherapy[1]. In metastatic NSCLC with an oncogenic driver, BM incidence is up to 60%[2]. BM incidence of small cell lung cancer (SCLC) patients is even higher (up to 80% at autopsy)[3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research
This article provides guidance to advanced practice providers (e.g., nurses, nurse practitioners, physician assistants) and oncology pharmacists for the clinical management of key lorlatinib-emergent adverse reactions (i.e., hyperlipidemias, central nervous system effects, bodyweight increase, edema, and peripheral neuropathy). As lorlatinib is both a substrate and inducer of the CYP3A enzyme system and is contraindicated with strong CYP3A inducers, relevant drug-drug interactions are also highlighted.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: In summary, there is no evidence of a demonstrable overall survival benefit with the addition of anti-EGFR therapy in first-line and recurrent glioblastomas. Newer drugs that are specially designed for glioblastoma targets may raise the possibility of success in this population, but data are lacking at present. Future studies should be more selective in pursuing people displaying specific EGFR targets. PMID: 32395825 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Authors: Milligan MG, Cronin AM, Colson Y, Kehl K, Yeboa DN, Schrag D, Chen AB Abstract BACKGROUND: Among patients diagnosed with stage IA non-small cell lung cancer (NSCLC), the incidence of occult brain metastasis is low, and several professional societies recommend against brain imaging for staging purposes. The goal of this study was to characterize the use of brain imaging among Medicare patients diagnosed with stage IA NSCLC. METHODS: Using data from linked SEER-Medicare claims, we identified patients diagnosed with AJCC 8th edition stage IA NSCLC in 2004 through 2013. Patients were classified as having r...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Introduction: Following the resection of brain metastases (BM), whole-brain radiotherapy (WBRT) is a long-established standard of care. Its position was recently challenged by the less toxic single-session radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) of the resection cavity, reducing dose exposure of the healthy brain.Patients and Methods: We analyzed 101 patients treated with either SRS/FSRT (n = 50) or WBRT (n = 51) following BM resection over a 5-year period. Propensity score adjustment was done for age, total number of BM, timepoint of BM diagnosis, controlled primary and extracranial metastases....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Alimta | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Heart | Liver | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study | Toxicology | Transplants | Urology & Nephrology